Publications<\/h2>\n\t\t\t\t![\"902_aran\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/04\/902_aran.png\" "\\"902_aran\\"")
\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tIdentification and characterisation of new immunomodulatory proteins and evaluation of their relevance and therapeutic potential in immune-mediated inflammatory diseases.
\nAnalysis of new diagnostic\/prognostic biomarkers in acute and chronic inflammatory pathologies.
\nOxidative stress in epithelial cells of the respiratory pathways. Inflammatory molecular mechanisms.\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t– Serrano I, Luque A, Mitjavila F, Blom AM, Rodr\u00edguez de C\u00f3rdoba S, Vega MC, Torras J, Aran JM. The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity<\/strong>. Front. Immunol. 2022;13883743-883743. doi:10.3389\/fimmu.2022.883743.<\/p>\n– Checa J, Martinez Gonzalez I, Maqueda M, Mosquera JL, Aran JM. Genome-Wide RNAi Screening Identifies Novel Pathways\/Genes Involved in Oxidative Stress and Repurposable Drugs to Preserve Cystic Fibrosis Airway Epithelial Cell Integrity<\/strong>. Antioxidants. 2021;10(12):doi:10.3390\/antiox10121936.<\/p>\n– Hueso M, Mall\u00e9n A, Su\u00f1\u00e9 Pou M, Aran JM, Su\u00f1\u00e9 Negre JM, Navarro E. ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery.<\/strong> Int J Mol Sci. 2021;22(21):doi:10.3390\/ijms222111596.<\/p>\n– Guiteras J, Ripoll E, Bolanos N, de Ramon L, Fontova P, Lloberas N, Cruzado JM, Aran JM, Avino A, Eritja R, Goma M, Taco R, Grinyo JM, Torras J. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis<\/strong>. Mol. Ther. Nucl. Acids. 2021;24807-821. doi:10.1016\/j.omtn.2021.03.019.<\/p>\n– Hueso M, Mallen A, Ripoll E, de Ramon L, Bolanos N, Varela C, Guiteras J, Checa J, Navarro E, Grinyo JM, Cruzado JM, Aran JM, Torras J. In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining<\/strong>. Bio-protocol. 2021;11(10):doi:10.21769\/BioProtoc.4032.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t21FIS019. Caracterizaci\u00f3n, potencial diagn\u00f3stico y terape\u00fatico de un nuevo inmunomodulador biol\u00f3gico para el tratamiento de enfermedades autoinmunes<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 171820. 2021-2023. PI: Aran Perramon, Josep M\u00aa.<\/p>\nAGA21005. PROGRAMA BEATRIU DE PINOS 2020<\/strong>. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 144300. 2022-2025. PI: Aran Perramon, Josep M\u00aa.<\/p>\n21FIS011. Desarrollo de un nuevo biol\u00f3gico restaurador de la tolerancia inmunitaria. Aplicaci\u00f3n al tratamiento de la enfermedad inflamatoria intestinal<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 115500. 2021-2023. PI: Aran Perramon, Josep M\u00aa.<\/p>\nFIS21142. CONTRATOS SARA BORRELL<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 95000. 2022-2022. PI: Aran Perramon, Josep M\u00aa.<\/p>\nAGA22021. PurPose Biotherapeutics: first-in-class metabolic modulators against autoimmune diseases<\/strong>. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 84000,06. 2022-2024. PI: Aran Perramon, Josep M\u00aa.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT10- “Compositions and methods for immunomodulation”
\nIP: Josep Maria Aran
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP11382240
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 15\/07\/11
\nPCT APPLICATION: PCT\/EP2012\/063932 (16\/07\/12)\nPAT057-Predictive methods of atherosclerosis and stenosis
\nEP16382025
\nIP: Josep Maria Aran, Ana Luque\nPAT62- “C4BP-based compounds for treating immunological diseases”
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP17382187
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 06\/04\/17
\nPCT APPLICATION: PCT\/EP2018\/058773 (06\/07\/18)\nPAT76- “Compounds for immunomodulation”
\nINVENTORS: Aran, J.M., Luque, A., Serrano, I.
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP19382910
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 17\/10\/19\nLicense: ISR-TEST: Test r\u00e0pid pel diagn\u00f2stic del risc d’ICTUS
\nPI: Dr. Josep Maria Aran\n\t\t\t\t![\"Aran](\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/aran-perramon-jose-maria-150x150.jpg\" "\\"aran-perramon-jose-maria\\"")
\n\n\t\tAran Perramon, Jose Maria\n\t<\/h4>\n\n\t\t\n\t\tjaran@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\n\n\t\tAran Perramon, Jose Maria\n\t<\/h4>\n\n\t\t\n\t\tjaran@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t\n- Aran Perramon, Jose Maria<\/li>\n<\/ul>\n\t\t\t\t\t\tPostdoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t
\n- Luque Gomez, Ana<\/li>\n
- Serrano Santacruz, Inmaculada<\/li>\n<\/ul>\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\thna Foundation collaborates in the development of a new drug against inflammatory bowel diseases<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t19\/12\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers present a new recombinant protein that reverses the proinflammatory state of cells in patients with lupus<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/05\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tFinding new paths in the treatment of cystic fibrosis<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL offers 10 projects for incoming INPhINIT fellowships<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tFunding to study new drugs against autoimmune diseases<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/10\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers discover that a molecule of blood is effective against autoimmune kidney disease<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/02\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPaperdrop Diagnostics, IDIBELL and M\u00fatuaTerrassa collaborate in the design of the first quick test to predict ischemic stroke<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/02\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and the Llobregat Business Forum, together in the 1st Research charity night<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/11\/2016\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tGenetically modified stem cells are effective against acute respiratory diseases<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t13\/06\/2013\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and VHIR licenses Histocell a patent for acute respiratory diseases with stem cells<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/03\/2013\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"Immune-inflammatory Processes and Gene Therapeutics Summary The Immune-inflammatory Processes and Gene Therapy research group carries out translational research with a primary focus on the molecular basis of immune-inflammatory processes. Its aim is to promote relevant, high-quality research into inflammation and to provide an optimal environment for training young researchers. 88 Publications Strategic lines Expand […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":552,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 04:58:15","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2696"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696\/revisions"}],"predecessor-version":[{"id":22544,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696\/revisions\/22544"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/552"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
– Checa J, Martinez Gonzalez I, Maqueda M, Mosquera JL, Aran JM. Genome-Wide RNAi Screening Identifies Novel Pathways\/Genes Involved in Oxidative Stress and Repurposable Drugs to Preserve Cystic Fibrosis Airway Epithelial Cell Integrity<\/strong>. Antioxidants. 2021;10(12):doi:10.3390\/antiox10121936.<\/p>\n – Hueso M, Mall\u00e9n A, Su\u00f1\u00e9 Pou M, Aran JM, Su\u00f1\u00e9 Negre JM, Navarro E. ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery.<\/strong> Int J Mol Sci. 2021;22(21):doi:10.3390\/ijms222111596.<\/p>\n – Guiteras J, Ripoll E, Bolanos N, de Ramon L, Fontova P, Lloberas N, Cruzado JM, Aran JM, Avino A, Eritja R, Goma M, Taco R, Grinyo JM, Torras J. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis<\/strong>. Mol. Ther. Nucl. Acids. 2021;24807-821. doi:10.1016\/j.omtn.2021.03.019.<\/p>\n – Hueso M, Mallen A, Ripoll E, de Ramon L, Bolanos N, Varela C, Guiteras J, Checa J, Navarro E, Grinyo JM, Cruzado JM, Aran JM, Torras J. In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining<\/strong>. Bio-protocol. 2021;11(10):doi:10.21769\/BioProtoc.4032.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 21FIS019. Caracterizaci\u00f3n, potencial diagn\u00f3stico y terape\u00fatico de un nuevo inmunomodulador biol\u00f3gico para el tratamiento de enfermedades autoinmunes<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 171820. 2021-2023. PI: Aran Perramon, Josep M\u00aa.<\/p>\n AGA21005. PROGRAMA BEATRIU DE PINOS 2020<\/strong>. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 144300. 2022-2025. PI: Aran Perramon, Josep M\u00aa.<\/p>\n 21FIS011. Desarrollo de un nuevo biol\u00f3gico restaurador de la tolerancia inmunitaria. Aplicaci\u00f3n al tratamiento de la enfermedad inflamatoria intestinal<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 115500. 2021-2023. PI: Aran Perramon, Josep M\u00aa.<\/p>\n FIS21142. CONTRATOS SARA BORRELL<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 95000. 2022-2022. PI: Aran Perramon, Josep M\u00aa.<\/p>\n AGA22021. PurPose Biotherapeutics: first-in-class metabolic modulators against autoimmune diseases<\/strong>. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 84000,06. 2022-2024. PI: Aran Perramon, Josep M\u00aa.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT10- “Compositions and methods for immunomodulation” Immune-inflammatory Processes and Gene Therapeutics Summary The Immune-inflammatory Processes and Gene Therapy research group carries out translational research with a primary focus on the molecular basis of immune-inflammatory processes. Its aim is to promote relevant, high-quality research into inflammation and to provide an optimal environment for training young researchers. 88 Publications Strategic lines Expand […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":552,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 04:58:15","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2696"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696\/revisions"}],"predecessor-version":[{"id":22544,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2696\/revisions\/22544"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/552"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Josep Maria Aran
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP11382240
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 15\/07\/11
\nPCT APPLICATION: PCT\/EP2012\/063932 (16\/07\/12)\nPAT057-Predictive methods of atherosclerosis and stenosis
\nEP16382025
\nIP: Josep Maria Aran, Ana Luque\nPAT62- “C4BP-based compounds for treating immunological diseases”
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP17382187
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 06\/04\/17
\nPCT APPLICATION: PCT\/EP2018\/058773 (06\/07\/18)\nPAT76- “Compounds for immunomodulation”
\nINVENTORS: Aran, J.M., Luque, A., Serrano, I.
\nOWNERSHIP:100% IDIBELL
\nREQUEST No.: EP19382910
\nPRIORITY COUNTRY: European Union
\nPRIORITY DATE: 17\/10\/19\nLicense: ISR-TEST: Test r\u00e0pid pel diagn\u00f2stic del risc d’ICTUS
\nPI: Dr. Josep Maria Aran\n\t\t\t\t\n\n\t\tAran Perramon, Jose Maria\n\t<\/h4>\n
\n\t\t\n\t\tjaran@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t
\n\n\t\tAran Perramon, Jose Maria\n\t<\/h4>\n
\n\t\t\n\t\tjaran@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\thna Foundation collaborates in the development of a new drug against inflammatory bowel diseases<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t19\/12\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers present a new recombinant protein that reverses the proinflammatory state of cells in patients with lupus<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/05\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tFinding new paths in the treatment of cystic fibrosis<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL offers 10 projects for incoming INPhINIT fellowships<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tFunding to study new drugs against autoimmune diseases<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/10\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers discover that a molecule of blood is effective against autoimmune kidney disease<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/02\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPaperdrop Diagnostics, IDIBELL and M\u00fatuaTerrassa collaborate in the design of the first quick test to predict ischemic stroke<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/02\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and the Llobregat Business Forum, together in the 1st Research charity night<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/11\/2016\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tGenetically modified stem cells are effective against acute respiratory diseases<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t13\/06\/2013\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and VHIR licenses Histocell a patent for acute respiratory diseases with stem cells<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/03\/2013\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"